Catalent is actively partnering with several customers on early-stage and feasibility projects for potential vaccines or treatments related to COVID-19 and exploring where we can help with other possible projects across our biologics, cell & gene therapy, oral technologies and analytical capabilities. We are treating these projects with utmost urgency, so that we may apply our expertise for the benefit of patients and their loved ones in this tragic situation. Contact us to find out more.

Last month, Catalent and Perrigo welcomed the news that the U.S. Food and Drug Administration (FDA) had approved the first generic hydrofluoroalkane (HFA) Metered Dose Inhaler (MDI). The approval marked a significant technical achievement, as it was the first generic MDI to be approved by the FDA since 1996. This new commercial offering adds to Catalent’s existing development and manufacturing capabilities across all common inhalation dosage forms. Perrigo’s launch of Albuterol Sulfate Inhalation Aerosol marks Catalent’s entry into commercial-scale MDI manufacturing, adding new capabilities to Catalent’s Research Triangle Park, North Carolina, facility, and bolstering its respiratory portfolio, which includes various formulation, development and manufacturing services.

BIOLOGICS

• Article: “Gene Therapy – Unprecedented Growth and Challenges” - Philip Wills, Chief Commercial Officer, Catalent Gene Therapy gives his insight on the latest trends and growth drivers in gene therapy, and strategies to overcome manufacturing challenges.
• e-book: “Frontiers in Binding Assays and Bioassays” - Bioassays and binding assays are integral to biologics development and manufacturing and play a critical role in ensuring product quality, safety and efficacy. Download the e-book to get expert insight on recent advances in bioassays and binding assays and how they are evolving to meet the demands of the industry.
• Webinar: “The Do’s and Don’ts of Managing a Pivotal Gene Therapy Trial” - Gene therapies have been exploding in popularity, with big and small players. But what does it take to de-risk a pivotal, registration-worthy gene therapy program? Hear the experts discuss ways of bringing gene therapies to market.
• Article: “Investments Inject Growth in Cell and Gene Therapies” - Colleen Floreck, senior director of Marketing and Communications at Catalent’s Paragon Gene Therapy is interviewed by PharmTech.com and discusses further collaborations, validating its proactive investment strategy in its Gene Therapy business.

 CLINICAL SUPPLY / CLINICAL SERVICES

• Article: “Beyond the Buy: The Critical Role of Data, Relationships, and Experience in Comparator Sourcing” - Successfully sourcing commercial products for comparative studies in an effective and efficient manner often proves far more challenging than assumed. Learn the key issues to take into account when developing a comprehensive sourcing plan.  
• Article: “How to Avoid Delays in Clinical Supply - Strategies for Comparator Sourcing” - Catalent’s Chris Greco, Manager of Comparator and Ancillary Supplies, discusses ways in which sponsors can work effectively with clinical suppliers for accurate forecasting and comparator sourcing.
• Executive Summary: “The Product Development Superhighway: Leveraging End-to-End Solutions for Market Success” - This article explores the benefits of an integrated approach in which the chemical, manufacturing, and controls (CMC) and clinical teams work together at an early stage to achieve greater success for both the development program and patients.

ORAL DRUG DELIVERY

• Webinar: “A Roadmap for Early Development to Commercial Manufacturing” - This webinar will use real-life examples to show how an integrated approach can help avoid common pitfalls in the transfer and scale-up process.

• Article: “Placing Patients at the Center of Drug Design” - Poor patient acceptance and adherence to medications continue to be some of the key challenges facing the healthcare and pharmaceutical industries. Learn strategies for formulation and dosage forms that developers can use to bring patient insights into the design of their drug products to potentially improve patient centricity.

• Video: “Catalent Zydis Fast Dissolve” - Whether you are considering an orally disintegrating tablet (ODT) to enhance pharmacokinetics through pre-gastric absorption, looking to improve patient compliance, or seeking a marketing advantage for a valued brand, Zydis® ODT technology can help enhance the value of your investment and accelerate your product’s potential.

• Article: “Improving Bioavailability & Solubility: Understand Your Molecule” - Catalent’s William Wei Lim Chin, PhD, Manager, Global Scientific Affairs, discusses how different approaches are critical to the success of small molecules. In this article Dr. Chin advises when successfully formulating a small molecule, the question of whether the molecule is dissolution-rate limited or solubility-limited for it to become systematically bioavailable must be addressed.
  

CONSUMER HEALTH

• Case Study: “Creating the Best-Selling ‘Beauty from Within’ Softgel Product Line” – Learn how Catalent’s formulation development and manufacturing expertise helped a topical skincare company successfully launch a brand-new ingestible supplement for the global market.
• e-book: “Innovations in Omega-3 Supplements” - Get expert insights on the latest advances in omega-3 delivery technology and explore new supplement ingredients that support brain, eye, and joint health.
• Video: “Launch Innovative Consumer Health Products Faster with Catalent” - Hundreds of Over-the-Counter, Nutritional Supplement and Beauty companies partner with us to bring innovative and consumer-preferred products faster to market. Watch this short video to learn more.

At Catalent, you will have the opportunity to thrive in a fast-paced, innovative environment where maximizing your potential isn’t just your own personal goal, it’s ours too. Our teams are rapidly growing in the greater Baltimore area, Bloomington, IN, Schorndorf, Germany and multiple other locations. Apply today!